These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29405611)

  • 1. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
    Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
    Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
    ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
    Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
    Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
    Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
    Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
    Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Cui D; Liao Y; Li G; Chen Y
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of levosimendan in elderly patients with severe heart failure].
    Wang YB; Yu YH; Gong SJ; Yan J; Wang Y
    Zhonghua Nei Ke Za Zhi; 2020 Jun; 59(6):433-438. PubMed ID: 32486583
    [No Abstract]   [Full Text] [Related]  

  • 8. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)].
    Xu F; Bian Y; Zhang GQ; Gao LY; Liu YF; Liu TX; Li G; Song RX; Su LJ; Zhou YJ; Cui JY; Yan XL; Guo FM; Zhang HY; Li QH; Zhao M; Ma LK; You BA; Wang G; Kong L; Ma JL; Zhou XF; Chang ZL; Tang ZY; Yu DY; Cheng K; Xue L; Li X; Pang JJ; Wang JL; Zhang HT; Yu XZ; Chen YG
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):374-383. PubMed ID: 37032132
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
    Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
    Cui XR; Yang XH; Li RB; Wang D; Jia M; Bai L; Zhang JD
    Cardiovasc J Afr; 2020; 31(4):196-200. PubMed ID: 32555927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L; Brito D; Matias JS; Madeira H
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
    Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
    Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
    Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
    Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
    Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
    J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
    García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
    ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.